

## Supporting Information

### **Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase**

*Taylor K. Johnson, Daniel A. Bochar, Nathalie M. Vandecan, Jessica Furtado, Michael P. Agius, Sameer Phadke, and Matthew B. Soellner\**

anie\_202105351\_sm\_miscellaneous\_information.pdf

## **TABLE OF CONTENTS**

<b>I.</b>	<b>Materials and Methods</b>	<b>Pages 2–3</b>
<b>II.</b>	<b>Single drug dose-response curves</b>	<b>Pages 4–5</b>
<b>III.</b>	<b>Analytical data for BaF3/ABL cellular synergy</b>	<b>Pages 6–17</b>
<b>IV.</b>	<b>Analytical data for InCELL Pulse cellular synergy</b>	<b>Pages 18–27</b>
<b>V.</b>	<b>Data for cleavage of Abl by thermolysin</b>	<b>Pages 28–31</b>
<b>VI.</b>	<b>Analytical data for Proteolysis Assay</b>	<b>Pages 32–40</b>
<b>VII.</b>	<b>References</b>	<b>Page 41</b>

## I. Materials and Methods.

**General Biochemical Methods.** Black, opaque-bottom 96 well plates were purchased from Nunc. All proteins were expressed in *E.coli* using previously published procedures.<sup>24</sup> Data were obtained using Biotek Synergy Mx and Biotek Synergy 4 plate readers. Curve fitting was done using Graphpad Prism 6 software.

**General Procedure for Proteolysis Half-Life Determination.** Assays employed a final concentration of 2  $\mu$ M abl, 10  $\mu$ M compound, and 60 nM thermolysin (Promega, V4001) in 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.5 mM CaCl<sub>2</sub>. Compounds and enzyme were allowed to equilibrate for 5 minutes at 20 °C prior to the addition of thermolysin. Reactions were sampled at various time points (2, 5, 10, 30, 60, 90, 120, 180, and 240 minutes) and quenched with 12.5 mM EDTA. Samples were analyzed using a PerkinElmer LabChip GX II with LabChip HT Protein Express Chips as per the manufacturer's instructions. Percent protein remaining was plotted versus time and fit to an exponential one phase decay equation using GraphPad Prism software (version 8.2) to obtain half-lives of each protein.

### **General procedure for cellular characterization.**

**1. Cell culture and seeding:** All Ba/F3 and K562 cell lines were cultured in RPMI 1640 media with 10% FBS. Parental Ba/F3 cell culture additionally contained 15% WEHI-3 conditioned media. An aliquot of the cells was mixed with Trypan Blue solution and the cell number was quantified using a hemocytometer. The cells were plated 100  $\mu$ L in each well at 30,000 cells/mL so that each well contained 3,000 cells. The cells were plated into sterile, clear bottom 96 well plates and then immediately dosed with compound. Additionally, 3 wells were created containing 100  $\mu$ L of media with no cells.

**2. Dosing:** The compounds were made in 100% DMSO at 1,000X the final concentrations that were desired for the assay generally covering a concentration range of 6 log units. These DMSO stocks were diluted 10X in RPMI 1640 media. 1  $\mu$ L of the compound diluted in media was added to each well for a final concentration of 0.1% DMSO. The wells containing only media were not dosed. In general, each compound concentration was dosed in triplicate wells. The plates were returned to normal culture conditions (per ATCC) for 72 hours.

**3. Assay:** After 72 hours, the plates were removed from the incubator, and 10  $\mu$ L of WST-1 reagent was added to each well. The plates were returned to the incubator and the color change was visually monitored for 0.5 – 2 hours. When sufficient color change had occurred, the plates were shaken on a plate shaker for 30 seconds, and absorbance at 450 and 630 nm was read in a Biotek Synergy 4 plate reader. The absorbance at 630 nm was subtracted from the absorbance at 450 nm.

**4. Data Analyses:** The average absorbance value from wells containing media without cells was subtracted from the absorbance value for all the wells containing cells. The absorbance values were then taken as a percentage of the absorbance for the vehicle wells (0.1% DMSO - no compound). The percent compared to vehicle was then plotted vs. log(Concentration). Data analyses and curve fitting were performed using Graphpad Prism 6. For each compound, there were n = 3 data points for each concentration. For curves that did not reach full inhibition, the bottom was set to -10.

### **General procedure for cellular synergy.**

**1. Cell culture and seeding:** All Ba/F3 and K562 cell lines were cultured in RPMI 1640 media with 10% FBS. Parental Ba/F3 cell culture additionally contained 15% WEHI-3 conditioned

media. An aliquot of the cells was mixed with trypan blue solution and the cell number was quantified using a hemacytometer. The cells were plated 100  $\mu$ L in each well at 30,000 cells/mL so that each well contained 3,000 cells. The cells were plated into sterile, clear bottom 96 well plates and then immediately dosed with compound.

**2. Dosing:** The compounds dilutions (2X) and combinations were made in 100% DMSO at 1,000X the final concentrations that were desired for the assay. These DMSO stocks were diluted 10X in RPMI 1640 media. 1  $\mu$ L of the compound diluted in media was added to each well for a final concentration of 0.1% DMSO. The wells containing only media were not dosed. In general, each compound concentration was dosed in triplicate wells. The plates were returned to normal culture conditions (per ATCC) for 72 hours.

**3. Assay:** After 72 hours, the plates were removed from the incubator and 10  $\mu$ L of WST-1 reagent was added to each well. The plates were returned to the incubator and the color change was visually monitored for 0.5 – 2 hours. When sufficient color change had occurred, the plates were shaken on a plate shaker for 60 seconds and read in a Biotek Synergy 4 plate reader.

**4. Data Analyses:** The average absorbance value from wells containing media without cells was subtracted from the absorbance value for all the wells containing cells. The data were then calculated as a fraction of the vehicle well (1% DMSO) and subtracted from 1 in order to represent the data as the fraction of population affected by the treatment at each given dose. The data were then analyzed using Compusyn to determine the combination indices.

#### Equation for Determination of Combination Index (CI)


$$CI = \frac{(D)_1}{(D_x)_1} + \frac{(D)_2}{(D_x)_2} = \frac{(D)_1}{(D_m)_1 \left[ \frac{f_a}{(1-f_a)} \right]^{1/m_1}} + \frac{(D)_2}{(D_m)_2 \left[ \frac{f_a}{(1-f_a)} \right]^{1/m_2}} \quad (1)^1$$

where (D)<sub>1</sub> and (D)<sub>2</sub> are the doses of drugs 1 and 2, D<sub>m</sub> is the dose required to produce the median effect (analogous to IC<sub>50</sub>, ED<sub>50</sub>, or LD<sub>50</sub> values), m is a Hill-type coefficient signifying the sigmoidicity of the dose-effect curve, and f<sub>a</sub> is fraction affected<sup>1</sup>

## II. Single drug dose-response curves


These dose-response curves were used to aid in the selection of optimal doses for the Chou-Talalay synergy experiments.

### BCR-Abl/BaF3:



	Dasatinib	Das-CHO	Das-DFGO	Imatinib	Nilotinib	Ponatinib	GNF-2	Asciminib
IC50	1.508e-010	1.427e-007	2.485e-010	5.972e-007	2.004e-008	1.736e-010	~ 2.926e-007	3.821e-010


**InCELL Pulse CETSA:**



	Dasatinib	DAS-CHO	DAS-DFGO	Imatinib	Nilotinib	Ponatinib	GNF-2	Asciminib
IC50	6.758e-009	2.303e-008	2.833e-008	1.267e-007	7.638e-009	2.084e-009	1.520e-006	1.044e-007

### III. Analytical Data for BCR-Ab/BaF3 Cellular Synergy

#### Dasatinib-GNF2





Drug/Combo	Dm	m	r
DAS	0.53773	-1.9520	-0.9527
GNF	360.769	-3.4430	-0.9956
DASGNF	105.274	-2.8634	-0.9523

CI values at:

Combo	ED50	ED75	ED90	ED95
DASGNF	1.07062	1.20546	1.37146	1.50509

## Dasatinib-Asciminib





Drug/Combo	Dm	m	r
DAS	0.49012	-2.0722	-0.9595
ASC	4.12004	-1.3464	-0.9695
DASASC	2.38456	-2.0298	-0.9990

CI values at:

Combo	ED50	ED75	ED90	ED95
DASASC	1.29319	1.43674	1.62859	1.79427



## Imatinib-GNF2





Drug/Combo	Dm	m	r
GNF	331.684	-3.3294	-0.9905
IMA	243.617	-2.2497	-0.9898
IMAGNF	287.416	-2.7159	-0.9727

CI values at:

Combo	ED50	ED75	ED90	ED95
IMAGNF	1.07537	1.12340	1.17893	1.22120

**Imatinib-Asciminib**





Drug/Combo	Dm	m	r
IMA	213.299	-2.0714	-0.9806
ASC	3.99456	-2.2695	-0.9544
IMAASC	158.173	-3.0529	-0.9606

CI values at:

Combo	ED50	ED75	ED90	ED95
IMAASC	1.12626	1.31462	1.53521	1.70650

## Nilotinib-GNF2





Drug/Combo	Dm	m	r
GNF	305.060	-2.2627	-0.9637
NILO	11.8307	-2.7963	-0.9969
NILGNF	149.888	-1.9798	-0.9948

CI values at:

Combo	ED50	ED75	ED90	ED95
NILGNF	1.59844	1.39624	1.22181	1.11698

## Nilotinib-Asciminib





Drug/Combo	Dm	m	r
NILO	12.5815	-2.6289	-0.9873
ASC	4.08488	-2.3880	-0.9650
NILASC	9.92739	-2.9080	-0.9892

CI values at:

Combo	ED50	ED75	ED90	ED95
NILASC	1.06259	1.12423	1.18995	1.23713

## Ponatinib-GNF2





Drug/Combo	Dm	m	r
GNF	217.943	-2.0843	-0.9505
PONA	0.68557	-3.5580	-0.9672
PONGNF	116.107	-3.7661	-0.9661

CI values at:

Combo	ED50	ED75	ED90	ED95
PONGNF	1.20535	1.35779	1.54781	1.70349

## Ponatinib-Asciminib





Drug/Combo	Dm	m	r
PONA	0.78362	-2.0072	-0.9606
ASC	3.64145	-2.2926	-0.9530
PONASC	2.56180	-4.0787	-0.9610

CI values at:

Combo	ED50	ED75	ED90	ED95
PONASC	1.13112	1.44261	1.84201	2.17656

## DAS-DFGO-II – GNF2





Drug/Combo	Dm	m	r
DFGO	1.64395	-4.8848	-0.9373
GNF	1313.29	-0.6030	-0.9969
DFGGNF	307.442	-1.0236	-0.9510

CI values at:

Combo	ED50	ED75	ED90	ED95
DFGGNF	1.34809	0.96943	1.24430	1.84496

**DAS-DFGO-II – Asciminib**





Drug/Combo	Dm	m	r
DFGO	1.95313	-3.0281	-0.9544
ASC	4.33040	-2.8843	-0.9888
DFGASC	3.53858	-3.4850	-0.9709

CI values at:

Combo	ED50	ED75	ED90	ED95
DFGASC	1.04667	1.10970	1.17662	1.22448



## DAS-CHO-II – GNF2





Drug/Combo	Dm	m	r
CHO	62.8500	-2.4836	-0.9935
GNF	350.039	-2.4789	-0.9646
CHO:GNF	158.014	-2.8688	-0.9513

CI values at:

Combo	ED50	ED75	ED90	ED95
CHO:GNF	0.79521	0.84420	0.89621	0.93340

## DAS-CHO-II – Asciminib




Drug/Combo	Dm	m	r
CHO	64.7249	-3.6691	-0.9960
ASC	4.25424	-3.1862	-0.9913
CHOASC	23.3313	-2.8485	-0.9801

CI values at:

Combo	ED50	ED75	ED90	ED95
CHOASC	0.82627	0.77921	0.73520	0.70689

## V. Analytical Data for InCELL Pulse CETSA Synergy

### Dasatinib-GNF2




Drug/Combo	Dm	m	r
DAS	16.2394	-0.8918	-0.9798
GNF	3507.01	-1.3245	-0.9506
DASGNF	358.707	-1.2181	-0.9838

CI values  
at:

Combo	ED95
DASGNF	1.13144

## Dasatinib-Asciminib





Drug/Combo	Dm	m	r
DAS	9.69257	-0.6764	-0.9662
ASC	570.043	-0.5555	-0.9852
DASASC	92.5031	-0.6796	-0.9496

CI values at:

Combo	ED95
DASASC	1.27397

## Imatinib-GNF2





Drug/Combo	Dm	m	r
IMA	166.378	-1.3318	-0.9978
GNF	1479.10	-1.3152	-0.9496
IMAGNF	948.220	-1.5973	-0.9974

CI values  
at:

Combo	ED95
IMAGNF	2.16487

## Imatinib-Asciminib




Drug/Combo	Dm	m	r
IMA	209.310	-0.9389	-0.9985
ASC	140.775	-0.8559	-0.9622
IMAASC	243.698	-0.9304	-0.9928

CI values  
at:

Combo	ED95
IMAASC	1.70554

## Nilotinib-GNF2





Drug/Combo	Dm	m	r
NILO	14.8299	-1.1627	-0.9654
GNF	1211.85	-0.9354	-0.9514
NILGNF	601.377	-1.0918	-0.9967

CI values at:

Combo	ED95
NILGNF	1.4382

## Nilotinib-Asciminib





Drug/Combo	Dm	m	r
NILO	21.2276	-1.0496	-0.9951
ASC	143.412	-1.0143	-0.9679
NILASC	114.248	-1.1152	-0.9988

CI values  
at:

Combo	ED95
NILASC	1.51862



## Ponatinib-GNF2




Drug/Combo	Dm	m	r
PON	3.81974	-1.1703	-0.9913
GNF	2079.03	-1.2593	-0.9894
PONGNF	244.710	-1.3122	-0.9982

CI values at:

Combo	ED95
PONGNF	0.96071

## Ponatinib-Asciminib




Drug/Combo	Dm	m	r
PONA	2.64755	-1.4674	-0.9883
ASC	70.0436	-1.1453	-0.9878
PONASC	43.0758	-1.3255	-0.9943

CI values at:

Combo	ED95
PONASC	1.45577

## DAS-DFGO-II – Asciminib





Drug/Combo	Dm	m	r
DFGO	38.7354	-1.1178	-0.9754
ASC	99.9675	-0.8204	-0.9879
DFGASC	142.498	-0.9308	-0.9689

CI values at:

Combo	ED95
DFGASC	2.17956

## DAS-CHO-II – Asciminib



Drug/Combo	Dm	m	r
CHO	36.2497	-1.2448	-0.9919
ASC	147.585	-0.9862	-0.9969
CHOASC	117.076	-0.9208	-0.9905

CI values at:

Combo	ED95
CHOASC	0.76886

## V. Data for cleavage of Abl by thermolysin

Abl is selectively cleaved after the GV residues in the kinase-SH2 linker:

ABL	NKPTVY <b>GV</b> SPN-YDKW
ABL2	NKPTVY <b>GV</b> SPI-HDKW
SRC	-PTSKPQTQ <b>GL</b> AKDAW
YES	-PTVKPQTQ <b>GL</b> AKDAW
FGR	-TIMKPQTL <b>GL</b> AKDAW
ITK	-RQKAPVTA <b>GL</b> RYGKW
BTK	-NKNAPSTA <b>GL</b> GYGSW
TEC	-GKNAPTTA <b>GF</b> SYEKW
TXK	-GSCLPATA <b>GF</b> SYEKW

### FULL LENGTH

Theoretical pI/Mw (average) for the user-entered sequence:

10 20 30 40 50 60  
GHMARWNSKE NLLAGPSEND PNLFVALYDF VASGDNTLSI TKGEKLRVLG YNHNGEWCEA

70 80 90 100 110 120  
QTKNGQGWPV SNYITPVNSL EKHSWYHGPV SRNAAEYLLS SGINGSFLVR ESESSPGQRS

130 140 150 160 170 180  
ISLRYEGRVY HYRINTASDG KLYVSSSESRF NTLAELVHHH STVADGLITT LHYPAPKRNK

190 200 210 220 230 240  
PTVYGVSPNY DKWEMERTDI TMKHKLGGGQ YGEVYEGVWK KYSLTVAVKT LKEDTMEVEE

250 260 270 280 290 300  
FLKEAAVMKE IKHPNLVQLL GVCTREPPFY IITEFMTYGN LLDYLRECNR QEVNAVVLLY

310 320 330 340 350 360  
MATQISSAME YLEKKNFIHR DLAARNCLVG ENHLVKVADF GLSRLMTGDT YTAHAGAKFP

370 380 390 400 410 420  
IKWTAPESLA YNKFSIKSDV WAFGVLLWEI ATYGMSPYPG IDLSQVYELL EKDYRMERPE

430 440 450 460 470  
GCPEKVYELM RACWQWNPSD RPSFAEIHQA FETMFQESSI SDEVEKELGK QGV

Mw: 53847.91

## CUT N\_TERM

Theoretical pI/Mw (average) for the user-entered sequence:

10            20            30            40            50            60  
GHMARWNSKE NLLAGPSEND PNLFVALYDF VASGDNTLSI TKGEKLRVLG YNHNGEWCEA

70            80            90            100            110            120  
QTKNGQGWPV SNYITPVNSL EKHSWYHGPV SRNAAEYLLS SGINGSFLVR ESESSPGQRS

130            140            150            160            170            180  
ISLRYEGRVY HYRINTASDG KLYVSSESRF NTLAELVHHH STVADGLITT LHYPAPKRNK

PTVY

Mw: 20566.80

## CUT C-TERM

Theoretical pI/Mw (average) for the user-entered sequence:

10            20            30            40            50            60  
VSPNYDKWEM ERTDITMKHK LGGGQYGEVY EGVWKKYSLT VAVKTLKEDT MEVEEFLKEA

70            80            90            100            110            120  
AVMKEIKHPN LVQLLGVCTR EPPFYIITEF MTYGNLLDYL RECNRQEVNA VVLLYMATQI

130            140            150            160            170            180  
SSAMEYLEKK NFIHRDLAAR NCLVGENHLV KVADFGLSRL MTGDTYTAHA GAKFPIKWTA


190            200            210            220            230            240  
PESLAYNKFS IKSDVWAFGV LLWEIATYGM SPYPGIDLSQ VYELLEKDYR MERPEGCPEK

250            260            270            280  
VYELMRACWQ WNPSDRPSFA EIHQAFETMF QESSISDEVE KELGKQGV


Mw: 33242.07

Cleavage of Abl by thermolysin over time. Peak at 33.7 is an internal control.


t = 2 min:




t = 5 min:



t = 60 min:



Full timecourse:







**VI. Analytical data for Protein Half Lives as Determined *via* Proteolysis Assay.**

	<b>Half Life (min)</b>	$\frac{T_{1/2}}{\text{WT Abl } T_{1/2}}$	<b>log(Relative Half Life)</b>
WT Abl	43.8 ± 5.7	1	0
SH3 Engaged Abl	169.8±20.5	3.87	0.59
A337N Abl	17.0±6.3	0.39	-0.41
Vehicle	29.3 ± 4.1	1	0
Dasatinib	2.7 ± 0.1	0.09	-1.05
Imatinib	2.3 ± 0.2	0.08	-1.1
Nilotinib	2.5 ± 0.1	0.09	-1.05
Ponatinib	2.3 ± 0.3	0.08	-1.1
GNF-2	367.5 ± 59.1	12.54	1.1
Asciminib	282.5 ± 17.9	9.64	0.98
Das-DFGO-II	2.2 ± 0.7	0.07	-1.15
Das-CHO-II	47.2 ± 7.9	1.61	0.21
Vehicle	25.4 ± 2.6	0.87	-0.06
GNF-2	330.7 ± 11	11.28	1.05
Asciminib	297 ± 24	10.13	1.01
GNF-2+Das-DFGO-II	22.5 ± 1.7	0.77	-0.11
GNF-2+Das-CHO-II	393.7 ± 12	13.43	1.13
Asciminib+Das-DFGO-II	19.9 ± 3	0.68	-0.17
Asciminib+Das-CHO-II	512.6 ± 22.7	17.49	1.24


**WT Abl**




**SH3 Engaged Abl**




A337N Abl




Vehicle




### Dasatinib




### Imatinib




### Nilotinib




### Ponatinib




### GNF-2




### Asciminib





DAS-DFGO-II




DAS-CHO-II








**Asciminib+DAS-DFGO-II**



**Asciminib+DAS-CHO-II**



## VII. References

- (1) Chou, T.-C.; Talalay, P. Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors. *Adv. Enzym. Regul.* **1984**, *22*, 27–55.